42.57
-1.05(-2.41%)
Currency In USD
| Previous Close | 43.62 |
| Open | 43.56 |
| Day High | 44.06 |
| Day Low | 42.12 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Volume | 539,932 |
| Average Volume | 886,517 |
| Market Cap | 3.04B |
| PE | -12.2 |
| EPS | -3.49 |
| Moving Average 50 Days | 44.64 |
| Moving Average 200 Days | 38.91 |
| Change | -1.05 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,279.92 as of August 20, 2025 at a share price of $42.57. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $1,337.42 as of August 20, 2025 at a share price of $42.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
GlobeNewswire Inc.
Aug 04, 2025 11:00 AM GMT
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
GlobeNewswire Inc.
Jun 27, 2025 3:56 AM GMT
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the
Kymera Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Jun 25, 2025 8:05 PM GMT
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha